Jara, AlejandroUndurraga, Eduardo A.Zubizarreta, José R.González, CeciliaAcevedo, JohannaPizarro, AlejandraVergara, VerónicaSoto-Marchant, MarioGilabert, RosarioFlores, Juan CarlosSuárez, PamelaLeighton, PaulinaEguiguren, PabloRíos, Juan CarlosFernández, JorgeGarcía-Escorza, HeribertoAraos, Rafael2023-07-102023-07-102022Jara, A., Undurraga, E.A., Zubizarreta, J.R. et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med 28, 1377–1380 (2022). https://doi.org/10.1038/s41591-022-01874-4https://repositorio.udd.cl/handle/11447/7683The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3–5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac’s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5–39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6–75.2) against hospitalization and 69.0% (95% CI, 18.6–88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3–5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.enEpidemiologyViral infectionArticlehttps://doi.org/10.1038/s41591-022-01874-4